Urothelial Bladder Cancer | Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Urothelial Bladder Cancer
Featuring perspectives from Prof Sia
Daneshmand, Dr Joshua J Meeks, Dr Matthew Milowsky and Prof J
Alfred Witjes, moderated by Dr Arlene Siefker‑Radtke, including the
following topics:
Introduction (0:00)
Current Role of Anti-PD-1/PD-L1 Antibodies in
the Treatment of Non-Muscle-Invasive Bladder Cancer — Joshua J
Meeks, MD, PhD (2:49)
Contemporary Management of Muscle-Invasive
Bladder Cancer — J Alfred Witjes, MD, PhD (26:30)
Novel Strategies Under Investigation for
Nonmetastatic Urothelial Bladder Cancer (UBC) — Sia Daneshmand, MD
(48:02)
Current and Future Up-Front Management of
Metastatic UBC (mUBC) — Matthew Milowsky, MD (1:12:26)
Selection and Sequencing of Therapy for
Relapsed/Refractory mUBC — Arlene Siefker-Radtke, MD (1:33:25)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.